SynthesisDrugs in R&D2018
Efficacy and Safety of Budesonide in the Treatment of Eosinophilic Esophagitis: Updated Systematic Review and Meta-Analysis of Randomized and Non-Randomized Studies.
Synthesis in Drugs in R&D, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Effect of budesonide oral suspension on dysphagia and esophageal inflammation in eosinophilic esophagitis: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- A meta-analysis on randomized controlled trials of treating eosinophilic esophagitis with budesonide.Annals of medicine · 2022Pooled it
- CD74-Targeting Antibody-Drug Conjugate Enhances Immunosuppression of Glucocorticoid in Systemic Lupus Erythematosus.International journal of molecular sciences · 2025Article
- Orally Dispersible Swallowed Topical Corticosteroids in Eosinophilic Esophagitis: A Paradigm Shift in the Management of Esophageal Inflammation.Pharmaceutics · 2025Review
- Eosinophilic esophagitis: Current concepts in diagnosis and management.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2024Review
- A retrospective real-world study on the safety and efficacy of budesonide orodispersible tablets for the induction therapy of eosinophilic oesophagitis.Therapeutic advances in gastroenterology · 2024Article
- Treatment of Pediatric Eosinophilic Esophagitis: Traditional and Novel Therapies.Current gastroenterology reports · 2023Review
- A Practical Update on Pediatric Eosinophilic Esophagitis.Children (Basel, Switzerland) · 2023Review
- Systemic administration of budesonide in pegylated liposomes for improved efficacy in chronic rhinosinusitis.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- A New Viscous Budesonide Formulation for the Treatment of Eosinophilic Esophagitis in Children: A Preliminary Experience and Review of the Literature.Journal of clinical medicine · 2022Article
- Formulations of Topical Steroids in Eosinophilic Esophagitis-Current Treatment and Emerging Possibilities.Journal of clinical medicine · 2022Review
- Predictive factors for glucocorticoid therapy in children with eosinophilic gastroenteritis.Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2021Article
- Eosinophilic Gastroenteritis-associated Duodenal Ulcer Successfully Treated with Crushed Budesonide.Internal medicine (Tokyo, Japan) · 2020Article
- Challenges and updates in the management of eosinophilic esophagitis.Przeglad gastroenterologiczny · 2020Review
- Diagnosis and treatment of eosinophilic esophagitis.The Journal of allergy and clinical immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
objectiveEosinophilic esophagitis (EE) is an immune/antigen-driven inflammation that causes esophageal dysfunction. Budesonide has shown promising effect in the management of EE in multiple studies, and we therefore conducted this systematic review/meta-analysis to assess budesonide efficacy and safety in order to provide more updated and robust evidence.
methodsIn April 2018, we conducted a systematic electronic search through four databases: PubMed, Scopus, Web of Science (ISI), and Cochrane Central. All original studies reporting the efficacy of budesonide in the treatment of EE were included in our meta-analysis. The Cochrane Collaboration tool was employed to assess the risk of bias among included randomized controlled trials, while the Newcastle-Ottawa Scale was used for non-randomized studies.
resultsA total of 12 studies including 555 participants were included in our review. Budesonide showed marked efficacy at the level of histological response compared to placebo [risk ratio (RR) (95% confidence interval (CI)) 11.93 (4.82-29.50); p > 0.001]. Analysis of randomized and non-randomized studies revealed considerable reduction in eosinophil count, with a mean difference (MD) (95% CI) of - 69.41 (- 105.31 to - 33.51; p < 0.001) and 46.85 (33.93-59.77; p < 0.001), respectively. Similarly, there was a marked improvement in the clinical symptoms via the analysis of randomized and non-randomized studies, with an RR (95% CI) of 1.72 (1.22-2.41; p = 0.002) and MD (95% CI) of 2.45 (0.76-4.15; p = 0.005), respectively.
conclusionBudesonide showed significant effect at all treatment endpoints. However, since budesonide carries a risk of candidiasis and our inferences are based only on a small number of included studies, more research is warranted to clarify these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.